Atherosclerosis
Volume 195, Issue 2 , Pages 277-286 , December 2007

Macrophage NADPH oxidase activation, impaired cholesterol fluxes, and increased cholesterol biosynthesis in diabetic mice: A stimulatory role for d-glucose

  • Tony Hayek

      Affiliations

    • Lipid research Laboratory, Faculty of Medicine, Technion, Rambam Medical Center, Haifa, Israel
    • These authors contributed equally to this work.
    • Corresponding Author InformationCorresponding author at: Internal Medicine Department E, Rambam Medical Center, 31096 Haifa, Israel. Tel.: +972 4 854 2059; fax: +972 4 854 2359.
    • ,
  • Marielle Kaplan

      Affiliations

    • Clinical Biochemistry Department, Rambam Medical Center, Haifa, Israel
    • These authors contributed equally to this work.
    • ,
  • Rachel Kerry

      Affiliations

    • Lipid research Laboratory, Faculty of Medicine, Technion, Rambam Medical Center, Haifa, Israel
    • ,
  • Michael Aviram

      Affiliations

    • Lipid research Laboratory, Faculty of Medicine, Technion, Rambam Medical Center, Haifa, Israel

Received 2 August 2006 ,Revised 14 December 2006 ,Accepted 22 December 2006.

References 

  1. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population: sixteen year follow-up study. Diabetes. 1974;23:105–111
  2. Uusitopa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. Five-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation. 1990;82:27–36
  3. Lusis AJ. Atherosclerosis. Nature. 2000;407:233–241
  4. Aviram M. Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases. Free Radic Res. 2000;33:S85–S97
  5. Steinberg D, Lewis A. Oxidative modification of LDL and atherogenesis. Circulation. 1997;95:1062–1071
  6. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: Basic mechanisms: oxidation inflammation and genetics. Circulation. 1995;91:2488–2496
  7. Aviram M, Hardak E, Vaya J, et al. Human serum paraoxonases Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation. 2000;30:2510–2517
  8. Rosenblat M, Draganov D, Watson CE, et al. Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Arterioscler Thromb Vasc Biol. 2003;23:468–474
  9. Rosenblat M, Aviram M. Nutritional pharmacological and metabolic influences on paraoxonase. Curr Opin Lipidol. 2005;16:393–399
  10. Aviram M, Rosenblat M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol. 2005;16:393–399
  11. Maziere C, Auclair M, Rose-Robert F, Leflon P, Maziere JC. Glucose-enriched medium enhances cell-mediated low density lipoprotein peroxidation. FEBS Lett. 1995;363:277–279
  12. Griffin E, Re A, Hamel N, et al. A link between diabetes and atherosclerosis: glucose regulates expression of CD36 at the level of translation. Nat Med. 2001;7:840–846
  13. Hayek T, Hussein K, Aviram M, et al. Macrophage-foam cell formation in streptozotocin-induced diabetic mice: stimulatory effect of glucose. Atherosclerosis. 2005;183:25–33
  14. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998;101:1581–1590
  15. Royall JA, Ischiropoulos H. Evaluation of 2′,7′-dichlorofluorescin and dihydrorhodamine 123 as fluorescent probes for intracellular H2O2 in cultured endothelial cells. Arch Biochem Biophys. 1993;302:348–355
  16. Maor I, Kaplan M, Hayek T, et al. Oxidized monocyte-derived macrophages in aortic atherosclerotic lesion from E0 mice and from human carotid artery contain lipid peroxides and oxysterols. Biochem Biophys Res Commun. 2000;269:775–780
  17. Aviram M, Vaya J. Markers for LDL oxidation. Methods Enzymol. 2001;335:244–256
  18. Shamir R, Hartman C, Karry R, et al. Paraoxonases (PONs) 1, 2, 3 are expressed in human and in mice gastrointestinal tract and in human intestinal Caco2cell line: selective secretion of PON1 and PON2. Free Radic Biol Res. 2005;39:336–344
  19. Johnston RB, Keele BB, Mirsa HP, et al. The role of superoxide anion generation in phagocytic bactericidal activity. J Clin Invest. 1975;55:1357–1372
  20. Kaplan M, Aviram M, Knopf C, Keidar S. Angiotensin II reduces macrophage cholesterol efflux: a role for the AT-1 receptor but not for the ABC1 transporter. Biochem Biophys Res Commun. 2002;290:1529–1534
  21. Fuhrman B, Volkova N, Aviram M. Pomegranate juice inhibits oxidized LDL uptake and cholesterol biosynthesis in macrophages. J Nutr Biochem. 2005;16:570–576
  22. Rozenberg O, Shih DM, Aviram M. Human serum paraoxonase decreases macrophage cholesterol biosynthesis: a possible role for its phospholipase A2-like activity and lysophosphatidylcholine formation. Arterioscler Thromb Vasc Biol. 2003;23:461–467
  23. Han J, Hajjar DP, Febbraio M, Nicholson AC. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. J Biol Chem. 1997;272:21654–21659
  24. Mietus-Snyder M, Gowri MS, Pitas RE. Class A scavenger receptor up-regulation in smooth muscle cells by oxidized low density lipoprotein. Enhancement by calcium flux and concurrent cyclooxygenase-2 up-regulation. J Biol Chem. 2000;275:17661–17670
  25. Iida KT, Kawakami Y, Suzuki H, et al. PPAR gamma ligands, troglitazone and pioglitazone, up-regulate expression of HMG-CoA synthase and HMG-CoA reductase gene in THP-1 macrophages. FEBS Lett. 2002;520:177–181
  26. Rosenblat M, Aviram M. Oxysterol-induced activation of macrophage NADPH-oxidase enhances cell-mediated oxidation of LDL in the atherosclerotic apolipoprotein E deficient mouse: inhibitory role for vitamin E. Atherosclerosis. 2002;160:69–80
  27. Cathcart MK. Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contributions to atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:23–282003
  28. Mackness B, McElduff P, Mackness MI. J Intern Med. 2005;258:363–368
  29. Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis. 2006;187:74–81
  30. Lagor William R, de Groh Eric D, Nes Gene C. Diabetes alters the occupancy of the hepatic 3-hydroxy-3-methylglutaryl-CoA reductase promoter. J Biol Chem. 2005;280:36601–36608
  31. Rosenson RS. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Am J Cardiovasc Drugs. 2001;1:411–420
  32. Fukuhara-Takaki K, Sakai M, Sakamoto Y, Takeya M, Horiuchi S. Expression of class A scavenger receptor is enhanced by high glucose in vitro and under diabetic conditions in vivo: one mechanism for an increased rate of atherosclerosis in diabetes. J Biol Chem. 2005;280:3355–3364

PII: S0021-9150(07)00036-6

doi: 10.1016/j.atherosclerosis.2006.12.026

Atherosclerosis
Volume 195, Issue 2 , Pages 277-286 , December 2007

Article Tools

* Image Usage & Resolution